Informa Pharma Intelligence Authors:Patricia Giglio, Content Manager, Medtrack; Patricia Reilly, VP, Intelligence Alliances and Unification; Doro Shin, Thought Leadership Manager; Steven Muntner, VP, Deals
Alliances are an intrinsic component of the pharma industry, allowing companies to maximize value and mitigate risk of their internal R&D investments. In 2016, Pharma Intelligence combined data from Medtrack with anonymized meeting data from BIO-Europe® to elucidate key trends and better understand the state of collaboration within the industry. In this updated edition of “Partnering in the Pharma World: BIO-Europe® and Industry Trends 2017 Update”, we revisit the partnering landscape, first by assessing currently available opportunities found within unpartnered assets for both publicly-traded and private companies. We then return to BIO-Europe, comparing 2016 meeting data with years past to analyze this crucial aspect of the partnering process, before wrapping up with the dealmaking activity that took place from H2 2016 through H1 2017, providing a glimpse into where these forged alliances could potentially lead.
- Both private and publicly-traded companies continue to use partnerships to advance their pipelines.
- Opportunity for partnering is most abundant at very early phases of development for both company types. Once drugs hit the clinic, almost twice as many unpartnered assets remain with publicly-traded companies than with private companies.
- Potential collaborations emerged with global companies in the private sector offering new classes of drugs and technologies across all therapy areas, and next generation immunotherapies in oncology.
- Attractive partnering options with public companies were identified this year, especially those with limited cash. Newcomers include companies with unpartnered cell therapies and orphan drugs.
- As biotech companies are increasingly looking towards their peers for partnering opportunities, it appears that pharma is significantly increasing the number of meeting requests to biotech companies in order to sustain partnerships between the two sectors.